Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
A Slc5a6-deficient mouse model reveals metabolically driven cardiomyopathy with therapeutic potential for vitamin-based intervention
Millie O. Fullerton, Lauren C. Phillips, Rachael E. Redgrave, Luke Spray, Vincent Haufroid, George Merces, Scott T. Kerridge, Gavin D. Richardson, Nathalie Mercier, Dominique Roland, Rebecca Crossley, Andrew D.H. Morgan, Joseph P. Dewulf, John Burn, Simon D. Bamforth, Helen M. Phillips
Millie O. Fullerton, Lauren C. Phillips, Rachael E. Redgrave, Luke Spray, Vincent Haufroid, George Merces, Scott T. Kerridge, Gavin D. Richardson, Nathalie Mercier, Dominique Roland, Rebecca Crossley, Andrew D.H. Morgan, Joseph P. Dewulf, John Burn, Simon D. Bamforth, Helen M. Phillips
View: Text | PDF
Research Article Cardiology Metabolism

A Slc5a6-deficient mouse model reveals metabolically driven cardiomyopathy with therapeutic potential for vitamin-based intervention

  • Text
  • PDF
Abstract

The sodium-dependent multivitamin transporter, encoded by SLC5A6, mediates cellular uptake of biotin and pantothenic acid, essential cofactors for energy metabolism. We identified 2 families with SLC5A6 mutations presenting with early-onset dilated cardiomyopathy (DCM). To investigate the link between vitamin deficiency and cardiomyopathy, we generated a cardiac-specific SLC5A6-knockout (Slc5a6cKO) mouse model and evaluated the impact of vitamin supplementation. Slc5a6cKO mice developed progressive cardiac dysfunction, culminating in cardiac pathology and premature death at 26 weeks; earlier stages exhibited cardiomyocyte hypertrophy, fibrosis, impaired coenzyme A synthesis, and metabolic imbalance, indicating progression toward cardiomyopathy. Cardiac magnetic resonance imaging and ECG confirmed progressive functional decline. Proteomic analysis revealed early mitochondrial metabolic disruption and extracellular matrix protein upregulation at 8 weeks, preceding overt cardiac dysfunction. Strikingly, vitamin supplementation from preconception onwards prevented the cardiac phenotype, preserving cardiac structure, function, morphology and survival. This paralleled the clinical outcome in one patient who received early vitamin treatment, compared with another who required a heart transplant without vitamin treatment. This study establishes a direct link between SLC5A6-mediated vitamin transport, mitochondrial function, and cardiac health. It highlights how vitamin deficiency contributes to cardiomyopathy pathogenesis and supports early vitamin supplementation as a potential therapeutic strategy for metabolic cardiomyopathies.

Authors

Millie O. Fullerton, Lauren C. Phillips, Rachael E. Redgrave, Luke Spray, Vincent Haufroid, George Merces, Scott T. Kerridge, Gavin D. Richardson, Nathalie Mercier, Dominique Roland, Rebecca Crossley, Andrew D.H. Morgan, Joseph P. Dewulf, John Burn, Simon D. Bamforth, Helen M. Phillips

×

Figure 5

Reduced vitamin transport in hearts from Slc5a6cKO hearts.

Options: View larger image (or click on image) Download as PowerPoint
Reduced vitamin transport in hearts from Slc5a6cKO hearts.
(A–M) Metabol...
(A–M) Metabolic analysis revealed significant increases in 3-HIA and 2-MCA in Slc5a6cKO mutants (n = 6) compared with controls (n = 5) (A and B). (C–I) Acylcarnitine analysis of plasma showed significant increases in C0, C5OH, C5OH/C0 ratio, C3DC, C6, C8, and C14 in Slc5a6cKO mutants (n = 6) compared with controls (n = 5). (J–M) Reduced pantothenic acid uptake was observed in Slc5a6cKO mutants (J) as well as a significant decrease in PA, PPA, PP, and CoAG. (N–W) In heart protein samples (n = 3–4 for each genotype), a decrease in PCC/MCC biotinylation was observed in Slc5a6cKO mutants at 5 and 20 weeks (N and P), with no corresponding change in liver samples (O and Q). In vitamin-supplemented Slc5a6cKO mutants, PCC/MCC biotinylation levels in the hearts were comparable to controls (R). No change in PC was observed in the hearts or livers (S–W). Data are represented as mean ± SEM. ns, nonsignificant. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 by unpaired t test for 2-sample comparisons. 3-HIA, 3-hydroxyisovaleric acid; 2-MCA, 2-methylcitric acid; C0, free carnitine; C5OH, 3-hydroxyisovaleryl-carnitine; C3DC, malonylcarnitine; C6, hexanoylcarnitine; C8, octanoylcarnitine; C14, tetradecanoylcarnitine; PA, pantothenic acid; PPA, phosphopantothenic acid; PP, phosphopantetheine; CoAG, CoA-glutathione; MCC, 3-methylcrotonyl-CoA carboxylase; PCC, propionyl-CoA carboxylase; PC, pyruvate carboxylase; Con, control; cKO, Slc5a6cKO; ConV, vitamin-supplemented control; cKOV, vitamin-supplemented Slc5a6cKO.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts